IntelGenx Technologies Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Dwight Gorham

Chief Executive Officer (CEO)

US$819.6k

Compensación total

Porcentaje del salario del CEO	20.2%
Permanencia del CEO	1.1yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.2yrs
Promedio de permanencia en la Junta Directiva	8.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Dwight Gorham en comparación con los beneficios de IntelGenx Technologies?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$820k	US$165k	-US$10m

Compensación vs. Mercado: La compensación total de Dwight($USD819.56K) está por encima de la media de empresas de tamaño similar en el mercado German ($USD406.12K).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Dwight con los resultados de la empresa.

CEO

Dwight Gorham (65 yo)

1.1yrs

Permanencia

US$819,564

Compensación

Mr. Dwight Gorham serves as Chief Executive Officer of IntelGenx Technologies Corp. since April 13, 2023 and also Joined the company on April 13, 2023. He served as the Chief Executive Officer and Presiden...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Dwight Gorham	Chief Executive Officer	1.1yrs	US$819.56k	sin datos
André Godin	President & CFO	8.8yrs	US$422.32k	0.44% $ 114.2k
Tommy Kenny	Senior VP & General Counsel	3.3yrs	US$176.92k	0.13% $ 32.7k
Nadine Paiement	Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp	no data	US$163.33k	0.093% $ 24.0k
Karen Kalayajian	Vice President of Finance & Administration	1.1yrs	sin datos	0.16% $ 41.6k
Stephen Kilmer	Investor Relations Officer	no data	sin datos	sin datos
Ingrid Zerbe	Corporate Secretary	18.1yrs	sin datos	0.053% $ 13.8k
Zenoz Pourhassan	VP of Quality Operations of Subsidiary	less than a year	sin datos	sin datos

2.2yrs

Permanencia media

52.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0IL se considera experimentado (2.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Nadine Paiement	Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp	8.3yrs	US$163.33k	0.093% $ 24.0k
Mark Nawacki	Independent Vice Chairman	7.8yrs	US$83.59k	0% $ 0
Clemens Mayr	Director	8.8yrs	US$75.57k	0% $ 0
Horst Zerbe	Chairman & Chairman of Scientific Advisory Board	18.1yrs	US$216.39k	0.0026% $ 670.2
Serge Gauthier	Member of Scientific Advisory Board	no data	sin datos	sin datos
Bernd Melchers	Independent Director	15.1yrs	US$83.59k	0.069% $ 17.7k
Barry Greenberg	Member of Scientific Advisory Board	8.3yrs	sin datos	sin datos
Ludwig Aigner	Member of Scientific Advisory Board	8.3yrs	sin datos	sin datos
Ryan Barrett	Director	less than a year	sin datos	sin datos
Monika Trzcinska	Independent Director	2yrs	US$75.57k	sin datos
Sahil Kirpekar	Director	less than a year	sin datos	sin datos

8.3yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de 0IL se considera experimentada (8.2 años de antigüedad promedio).

IntelGenx Technologies Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

IntelGenx Technologies Corp., Annual General Meeting, May 07, 2024

IntelGenx Technologies Corp. Announces Changes to its Board of Directors

Less than half of directors are independent

IntelGenx Technologies Corp. Announces the Resignation of J. Bernard (Bernie) Boudreau from the Board of Directors

Less than half of directors are independent

IntelGenx Technologies Corp. Elects Monika Trzcinska As Director

Recent updates

Intelgenx Announces First Parkinson’S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ‘Montpark’ Clinical Trial

IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA

IntelGenx Technologies Corp., Annual General Meeting, May 07, 2024

New major risk - Financial position

Full year 2023 earnings released: US$0.057 loss per share (vs US$0.065 loss in FY 2022)

IntelGenx Technologies Corp. to Report Q4, 2023 Results on Mar 21, 2024

IntelGenx Technologies Corp. Announces Positive Results from Proof-Of-Concept Study to Assess the Palatability, Owner-Perceived Acceptability, and Ease of Repeated Administration of Intelgenx’s VetaFilm® Platform in Healthy Dogs and Cats

IntelGenx Technologies Corp. Announces Changes to its Board of Directors

IntelGenx Corp. Receives Approval to Conduct 'Montpark' Montelukast Versafilm Phase 2 Clinical Trial in Patients with Parkinson's Disease

Third quarter 2023 earnings released: US$0.016 loss per share (vs US$0.015 loss in 3Q 2022)

IntelGenx Technologies Corp. to Report Q3, 2023 Results on Nov 09, 2023

New minor risk - Shareholder dilution

Gensco® Pharma and Intelgenx Announces Rizafilm Commercialization Update in the United States

IntelGenx Corp. Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

IntelGenx Technologies Corp. announced that it expects to receive CAD 9.43492 million in funding from ATAI Life Sciences AG

IntelGenx Technologies Corp. announced that it expects to receive CAD 8.42041 million in funding from ATAI Life Sciences AG

Intelgenx Technologies Corp. Completes Enrollment for `Buena' Montelukast Versafilm® Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease

Second quarter 2023 earnings released: US$0.016 loss per share (vs US$0.017 loss in 2Q 2022)

IntelGenx Technologies Corp. to Report Q2, 2023 Results on Aug 14, 2023

Intelgenx Corp. Completes Enrollment for 'Buena' Montelukast Versafilm®? Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease

Intelgenx Corp. Provides Update on Research Collaboration Evaluating Montelukast Versafilm for the Treatment of Parkinson's Disease

Less than half of directors are independent

IntelGenx Technologies Corp. Announces the Resignation of J. Bernard (Bernie) Boudreau from the Board of Directors

First quarter 2023 earnings released: US$0.017 loss per share (vs US$0.017 loss in 1Q 2022)

IntelGenx Technologies Corp. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.065 loss per share (vs US$0.068 loss in FY 2021)

IntelGenx Corp. Receives FDA Pdufa Date for Rizafilm®

Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.013 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.013 loss in 3Q 2021)

IntelGenx Technologies Corp. to Report Q3, 2022 Results on Nov 10, 2022

IntelGenx Files Provisional U.S. Patent Application for Advanced Oral Film Formulation Improving Cannabinoid Onset of Action

IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

IntelGenx Corp. Submits Response to CRL from FDA for RIZAPORT VersaFilm

IntelGenx Announces Enrollment Reaches Halfway Mark in ‘BUENA’ Montelukast VersaFilm Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

Second quarter 2022 earnings released: US$0.017 loss per share (vs US$0.017 loss in 2Q 2021)

IntelGenx Technologies Corp. to Report Q2, 2022 Results on Aug 11, 2022

Less than half of directors are independent

IntelGenx Technologies Corp. Elects Monika Trzcinska As Director

IntelGenx Technologies Corp. to Report Q1, 2022 Results on May 12, 2022

First Patient Dosed in IntelGenx Technologies Corp. Resumed ‘Buena’ Montelukast Versafilm Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.015 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.015 loss in 2Q 2020)

IntelGenx Technologies Corp. announced that it has received $2.1 million in funding

First quarter 2021 earnings released: US$0.02 loss per share (vs US$0.024 loss in 1Q 2020)

Full year 2020 earnings released: US$0.065 loss per share (vs US$0.11 loss in FY 2019)

IntelGenx Technologies Corp. to Report Q4, 2020 Results on Mar 25, 2021

IntelGenx Technologies Corp., Annual General Meeting, May 11, 2021

IntelGenx Receives USPTO Notice of Allowance for its Novel DisinteQTM-Based Disintegrating THC Oral Film

IntelGenx Files Provisional U.S. Patent Application for Novel Vetafilmtm High Loading Oral Film Platform

New 90-day high: €0.30

Intelgenx Receives First Purchase Order for Cbd Filmstrips from Heritage Cannabis

New 90-day high: €0.22

Third quarter 2020 earnings released: US$0.015 loss per share

IntelGenx Corp. Announces Publication of a Study Evaluating Montelukast’s Effect on Neurological Aging

IntelGenx Technologies Corp. to Report Q3, 2020 Results on Nov 12, 2020

Heritage Cannabis Holdings Corp. Signs Letter of Intent with Intelgenx Technologies Corp. for Long-Term Cannabis Filmstrip Supply Agreement

IntelGenx Technologies Corp. announced that it has received $1.2 million in funding

First half earnings released

IntelGenx Technologies Corp. to Report Q2, 2020 Results on Aug 13, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad